The Seventh Circuit Court of Appeals has reversed a lower court's ruling that dismissed Teva Pharmaceuticals USA, Inc.'s breach of contract claims against Eli Lilly and Company. The case, Teva Pharmaceuticals USA, Inc. v. Eli Lilly and Company (No. 25-2125), centers on a settlement agreement related to the drug Forteo, which treats osteoporosis. The ruling could have significant implications for generic drug manufacturers and their ability to enter the market.
Teva Pharmaceuticals, a generic drug manufacturer, filed a lawsuit against Eli Lilly, a brand-name pharmaceutical company, claiming that Lilly violated a settlement agreement from a previous lawsuit. The dispute arose after Lilly allegedly took actions that delayed Teva's entry into the market for a generic version of Forteo. The Seventh Circuit's decision allows Teva's claims to proceed, which could impact the dynamics of the pharmaceutical market.
The conflict between Teva and Lilly began in 2016 when Lilly sued Teva for patent infringement related to Forteo. Teva had submitted an application to the FDA for a generic version of the drug, which led to the lawsuit under the Hatch-Waxman Act. This act allows generic manufacturers to challenge brand-name patents and potentially enter the market sooner. In 2018, the parties reached a settlement that allowed Teva to enter the market for a generic Forteo by a specified date, provided that Lilly would not obstruct this process.
The settlement agreement stipulated that Teva could not sell its generic version of Forteo until August 12, 2019, but in return, Lilly agreed not to take any actions that would prevent or delay Teva's approval or launch of the generic drug. However, after the patents for Forteo expired in August 2019, Teva claimed that Lilly's actions continued to obstruct its market entry, particularly when Lilly sought additional regulatory exclusivity for the drug.
In November 2024, Teva filed its lawsuit against Lilly, alleging breach of contract, unjust enrichment, and tortious interference. Teva argued that Lilly's actions after the patent expiration violated the settlement agreement, which Lilly contended had expired when the patents did. The district court agreed with Lilly and dismissed the case, leading Teva to appeal.
The Seventh Circuit, led by Judge Hamilton, reviewed the case and found that Teva had plausibly alleged breaches of the settlement agreement that were still in effect at the time of the alleged violations. The court stated, "The generic manufacturer has plausibly alleged breaches of contract terms that were still in effect." The ruling emphasized that the settlement agreement did not specify an expiration date, and the court found that it could reasonably be interpreted to continue beyond the expiration of the patents.
The court noted that the absence of a clear termination date in the agreement meant that it could remain in effect for a reasonable time. The judges pointed out that the agreement included provisions that could survive the expiration of the patents, particularly Lilly's covenant not to block Teva's entry into the market.
This ruling has significant implications for the pharmaceutical industry, particularly for generic manufacturers. If Lilly's actions are found to have violated the settlement agreement, it could set a precedent for how similar agreements are interpreted in the future. The decision could also encourage other generic manufacturers to pursue claims against brand-name companies that may attempt to extend their market exclusivity through regulatory means.
Going forward, Teva's claims will proceed in the lower court, where the parties will have the opportunity to present their arguments regarding the alleged breaches of the settlement agreement. The case highlights the ongoing tension between generic drug manufacturers and brand-name companies in the pharmaceutical industry.
As for next steps, it remains to be seen whether Eli Lilly will seek to appeal the Seventh Circuit's decision. If they choose to do so, it could lead to further legal battles regarding the interpretation of settlement agreements in the pharmaceutical sector. For now, the ruling allows Teva to continue its pursuit of claims against Lilly, potentially reshaping the landscape for generic drug competition.